USD 0.09
(0.0%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | 89.96 Thousand | 5963.00 | 4239.00 | - | - | 943.00 |
Gross Profit | -89.96 Thousand | -5963.00 | -4239.00 | - | - | -943.00 |
Operating Expenses | 443.08 Thousand | 1.95 Million | 2.33 Million | 4.07 Million | 549.63 Thousand | 591.76 Thousand |
Selling, General and Administrative Expenses | 443.08 Thousand | 537.65 Thousand | 673.52 Thousand | 860.08 Thousand | 533.57 Thousand | 509.76 Thousand |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | - | - | - | - | - | - |
Cost and Expenses | 533.05 Thousand | 1.95 Million | 2.33 Million | 4.07 Million | 549.63 Thousand | 592.7 Thousand |
Operating Income | -533.05 Thousand | -1.92 Million | -2.31 Million | -4.07 Million | -548.09 Thousand | -591.56 Thousand |
Interest Expense | - | 39.66 Thousand | 8199.00 | - | - | 836.00 |
Income Tax Expense | - | 39.66 Thousand | 8199.00 | -5505.28 | -1880.94 | 836.00 |
Earnings before Tax | -612 Thousand | -1.97 Million | -2.32 Million | -4.07 Million | -547.75 Thousand | -593.73 Thousand |
Net Income | -612 Thousand | -1.97 Million | -2.32 Million | -4.07 Million | -547.75 Thousand | -593.73 Thousand |
Earnings Per Share Basic | -0.01 | -0.04 | -0.05 | -0.14 | -0.03 | -0.04 |
Earnings Per Share Diluted | -0.01 | -0.04 | -0.05 | -0.14 | -0.03 | -0.04 |
Weighted Average Shares Outstanding | 56 Million | 55.81 Million | 45.27 Million | 29.54 Million | 19.48 Million | 14.29 Million |
Weighted Average Shares Outstanding (Diluted) | 55.99 Million | 55.81 Million | 45.27 Million | 29.54 Million | 19.48 Million | 14.29 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | -531.18 Thousand | -1.91 Million | -2.26 Million | - | -511.03 Thousand | -554.12 Thousand |
Earnings Before Tax Margin | - | - | - | - | - | - |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - |
Cost of Revenue | 931.00 | 1804.00 | 7217.00 | 1804.00 | 1805.00 | 1804.00 |
Gross Profit | -931.00 | -1804.00 | -7217.00 | -1804.00 | -1805.00 | -1804.00 |
Operating Expenses | 137.6 Thousand | 66.73 Thousand | 483.52 Thousand | 87.95 Thousand | 97.9 Thousand | 136.08 Thousand |
Selling, General and Administrative Expenses | 137.6 Thousand | 66.73 Thousand | - | 87.95 Thousand | 63.47 Thousand | 84.68 Thousand |
Research and Development Expenses | - | - | - | - | - | - |
Other Expenses | 48.87 Thousand | - | - | - | - | - |
Cost and Expenses | 138.53 Thousand | 68.53 Thousand | 490.74 Thousand | 89.75 Thousand | 97.9 Thousand | 136.08 Thousand |
Operating Income | -138.53 Thousand | -68.54 Thousand | -490.74 Thousand | -89.76 Thousand | -97.9 Thousand | -136.08 Thousand |
Interest Expense | 9082.00 | 7484.00 | - | 7607.00 | 8141.00 | 7935.00 |
Income Tax Expense | -1.00 | -4.00 | 3.00 | -4.00 | 8141.00 | 7935.00 |
Earnings before Tax | -151.42 Thousand | -72.79 Thousand | -612 Thousand | -185.6 Thousand | -105.76 Thousand | -143.45 Thousand |
Net Income | -151.42 Thousand | -72.79 Thousand | -612 Thousand | -185.6 Thousand | -105.76 Thousand | -143.45 Thousand |
Earnings Per Share Basic | -0.00 | -0.00 | - | -0.00 | -0.00 | -0.00 |
Earnings Per Share Diluted | -0.00 | -0.00 | - | -0.00 | -0.00 | -0.00 |
Weighted Average Shares Outstanding | 55.99 Million | 55.99 Million | 55.99 Million | 55.99 Million | 55.81 Million | 55.81 Million |
Weighted Average Shares Outstanding (Diluted) | 55.99 Million | 55.99 Million | 55.99 Million | 55.99 Million | 55.81 Million | 55.81 Million |
Gross Margin | - | - | - | - | - | - |
EBIT Margin | - | - | - | - | - | - |
Profit Margin | - | - | - | - | - | - |
EBITDA | -137.6 Thousand | -66.74 Thousand | - | -87.96 Thousand | -96.09 Thousand | -134.28 Thousand |
Earnings Before Tax Margin | - | - | - | - | - | - |
ANKOF
CTP2
MLD-M
SOLB
SMSPHARMA
002255